Patients concerns about treatment with biosimilars
Biosimilars are not going to be the same as the originator biologic drug and that scares a lot of patients and doctors. They want to see basically the biosimilars treated as new drugs. In this MEDtalk Steve Feldman, professor of dermatology, share his experience with biosimilars.
Få tilgang til artikkelen
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.